Clinical Trials Browser

Breast Neoplasms

Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck

Stomach Neoplasms

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

Breast Neoplasms, Neoplasms

Breast Cancer Metastatic

HER2-positive Breast Cancer

Breast Neoplasms

Stomach Neoplasms

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms

HER2-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Breast Neoplasm Female

Breast Neoplasms

Breast Neoplasms

Esophageal Squamous Cell Carcinoma

Breast Neoplasms

HER2-positive Breast Cancer

HER2+ Breast Cancer

Breast Neoplasms

Brain Neoplasms, Breast Neoplasms

Breast Neoplasms

Carcinoma, Transitional Cell

HER2-positive

HER2-positive Gastric Cancer

Colorectal Neoplasms

Breast Neoplasms

Intestinal Neoplasms, Colorectal Neoplasms

HER2-positive Breast Cancer

HER2-positive Breast Cancer

Estrogen Receptor-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Advanced Breast Cancer

Colorectal Neoplasms

Breast Neoplasms, Cardiotoxicity

Digestive System Neoplasms

Breast Neoplasms, Cardiotoxicity

Breast Neoplasms

Brain Neoplasms

HER2+ Early or Locally Advanced Breast Cancer

Stomach Neoplasms

Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer

Clinical Trials

Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer

TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

B2023-153

Safety and Efficacy of NK510 to Treat Gastric Cancer

ROME

BiOnHER

A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

Clinical Study to Evaluate the Efficacy and Safety of TQB2440 Injection/Perjeta® Combined With Trastuzumab and Docetaxel in the Treatment of Patients With Early or Locally Advanced Breast Cancer.

HIST-RIC

Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGC

Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer

VinCaT

FB-12

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

easy laugh

A Study of Pyrotinib in Combination With Trastuzumab and Docetaxel in Patients With HER2 Metastatic Breast Cancer

NeoPATH

Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer

Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower)

Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast Cancer

HERES

A Study of Immunotherapy Combined With Neoadjuvant Therapy Versus Neoadjuvant Therapy for Breast Cancer

Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients

Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China

Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab

A Study of Trastuzumab and Pyrotinib in HER2 Positive Locally Advanced or Metastatic Urothelial Carcinoma

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer

Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status

Efficacy and Safety of Precision Therapy in Refractory Tumor

A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Efficacy and Safety of Adjuvant Docetaxel and Trastuzumab in Stage I HER2-positive Breast Cancer

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

HERMET

NeoTPPF

NSABP Biospecimen Discovery Project

Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer

Screening Plasma HER2 Amplication by Digital PCR in Advanced Breast Cancer Patients Treated With Trastuzumab and Pyrotinib

A Clinical Study of Pyrotinib in Patients With HER2-positive Advanced Colorectal Cancer

Risk Assessment Model of Trastuzumab-related Cardiotoxicity in Breast Cancer Patients

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Evaluation of Heart Function in Breast Cancer Patients Using Trastuzumab

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Pyramid

Study of Ramucirumab, Trastuzumab and Paclitaxel in Patients With HER2-positive Recurrent/Metastatic Gastric Cancer (HER-RAM Study)

Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast Cancer